## Jinesh Gheeya

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4907461/publications.pdf

Version: 2024-02-01

		1163117	1588992	
9	209	8	8	
papers	citations	h-index	g-index	
9	9	9	495	
all docs	docs citations	times ranked	citing authors	
			495 citing authors	

#	Article	IF	CITATION
1	Clinical and Molecular Characterization of <i>POLE </i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precision Oncology, 2022, 6, e2100267.	3.0	28
2	715P Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC). Annals of Oncology, 2020, 31, S562-S563.	1.2	0
3	Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	16
4	Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma. Scientific Reports, 2017, 7, 5568.	3.3	37
5	Protein-lysine methyltransferases G9a and GLP1 promote responses to DNA damage. Scientific Reports, 2017, 7, 16613.	3.3	28
6	Development of Peptide Nucleic Acid Probes for Detection of the HER2 Oncogene. PLoS ONE, 2013, 8, e58870.	2.5	19
7	Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7337-7340.	2.2	26
8	Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor. Cancer Letters, 2010, 293, 124-131.	7.2	30
9	Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biology and Therapy, 2009, 8, 2386-2395.	3.4	25